{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T16:05:32Z","timestamp":1784563532421,"version":"3.55.0"},"reference-count":24,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Relapse limits survival after allogeneic hematopoietic cell transplant. Although human leukocyte antigen\u2013matched related donors (MRDs) are traditionally preferred, mismatched unrelated donors (MMUDs) using posttransplant cyclophosphamide may provide stronger graft-vs-leukemia effects, potentially altering donor selection strategies.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare outcomes between MRD and MMUD transplant in the posttransplant cyclophosphamide era and assess whether MMUD grafts are associated with lower relapse rates.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This retrospective cohort study (January 1, 2017, to August 31, 2024) assessed 1038 patients with acute leukemia or myelodysplastic syndromes and\/or myeloproliferative neoplasms undergoing their first peripheral blood hematopoietic cell transplant using posttransplant cyclophosphamide. The MRD cohort was from a single tertiary center, and the MMUD cohort was from the Center for International Blood and Marrow Transplant Research. Data were analyzed between January 19, 2026, and April 2, 2026.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Transplant from MRD (n\u2009=\u2009306) vs MMUD (n\u2009=\u2009732).<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Disease-free survival (DFS), overall survival (OS), relapse, nonrelapse mortality, and graft-vs-host disease (GVHD). The study used inverse probability of treatment weighting with overlap weights and bootstrapping to address structural confounding, particularly donor age. Cox proportional hazard models were used to compare outcomes between groups and confirm that phrasing with the author.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among 1038 patients (526 [50.7%] female), donors in the MRD group were older (median [IQR] age, 57 [45-64] years) than in the MMUD group (median [IQR] age, 28 [24-35] years) (\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). Recipient age was similar (median [IQR] age, 60 [47-66] vs 58 [47-65] years;\n P<\/jats:italic>\n \u2009=\u2009.40). In patients with a high or very high Disease Risk Index (DRI), MMUD transplant was associated with significantly lower relapse hazard vs MRD (weighted hazard ratio [HR], 0.56; 95% CI, 0.33-0.94;\n P<\/jats:italic>\n \u2009=\u2009.03), although DFS (HR, 0.71; 95% CI, 0.46-1.11;\n P<\/jats:italic>\n \u2009=\u2009.14) and OS (HR, 0.85; 95% CI, 0.53-1.37;\n P<\/jats:italic>\n \u2009=\u2009.51) were similar. Conversely, in patients with low to intermediate DRIs, hazard estimates for DFS (HR, 1.24; 95% CI, 0.92-1.66;\n P<\/jats:italic>\n \u2009=\u2009.16) and OS (HR, 1.36; 95% CI, 0.99-1.88;\n P<\/jats:italic>\n \u2009=\u2009.06) lacked precision. MMUD was associated with lower risk of grade III to IV acute GVHD (HR, 0.56; 95% CI, 0.32-0.98;\n P<\/jats:italic>\n \u2009=\u2009.04) but higher chronic GVHD (HR, 2.82; 95% CI, 2.02-3.95;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study, MMUD transplant was associated with lower relapse rates compared with MRD in patients with high-risk malignant tumors, potentially reflecting enhanced alloreactivity, although accompanied by increased chronic GVHD. These findings indicated that the immunologic role of human leukocyte antigen mismatch varies by disease risk, suggesting that MMUD grafts offered a distinct risk-benefit profile that warrants further investigation.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.23265","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T15:30:31Z","timestamp":1784561431000},"page":"e2623265","source":"Crossref","is-referenced-by-count":0,"title":["Mismatched Unrelated vs Matched Related Donor Transplant With Posttransplant Cyclophosphamide Among Patients With Blood Cancers"],"prefix":"10.1001","volume":"9","author":[{"given":"Rohtesh S.","family":"Mehta","sequence":"first","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosra M.","family":"Aljawai","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Partow","family":"Kebriaei","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren","family":"Fingrut","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Portia","family":"Smallbone","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betul","family":"Oran","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Olson","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uday","family":"Popat","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Champlin","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Shpall","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"issue":"8","key":"zoi260654r1","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jtct.2025.05.014","article-title":"Current activity trends and outcomes in hematopoietic cell transplantation and cellular therapy: a report from the CIBMTR.","volume":"31","author":"Spellman","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"zoi260654r2","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1038\/s41375-024-02256-0","article-title":"Improved survival with younger HLA-matched unrelated donors versus older matched sibling donor HCT with PTCy-prophylaxis.","volume":"38","author":"Ramdial","year":"2024","journal-title":"Leukemia"},{"issue":"8","key":"zoi260654r3","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/s41409-023-01997-3","article-title":"Should a matched sibling donor still be considered the primary option for allogeneic hematopoietic cell transplantation in patients over 50 years of age with myelodysplastic syndrome?","volume":"58","author":"Konuma","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"zoi260654r4","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1038\/s41375-025-02724-1","article-title":"Young unrelated donors confer a survival advantage for patients with myeloid malignancies compared to older siblings.","volume":"39","author":"Schetelig","year":"2025","journal-title":"Leukemia"},{"issue":"14","key":"zoi260654r5","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.1182\/bloodadvances.2024014858","article-title":"Transplant outcomes using older matched sibling donors compared with young alternative donors: a CIBMTR analysis.","volume":"9","author":"Nath","year":"2025","journal-title":"Blood Adv"},{"issue":"20","key":"zoi260654r6","doi-asserted-by":"publisher","first-page":"5306","DOI":"10.1182\/bloodadvances.2024013853","article-title":"Haploidentical vs HLA-matched sibling donor HCT with PTCy prophylaxis: HLA factors and donor age considerations.","volume":"8","author":"Mehta","year":"2024","journal-title":"Blood Adv"},{"issue":"28","key":"zoi260654r7","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1200\/JCO.24.00582","article-title":"Human leukocyte antigen mismatching and survival in contemporary hematopoietic cell transplantation for hematologic malignancies.","volume":"42","author":"Arrieta-Bola\u00f1os","year":"2024","journal-title":"J Clin Oncol"},{"issue":"28","key":"zoi260654r8","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1200\/JCO.24.00184","article-title":"Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis attenuates disparity in outcomes between use of matched or mismatched unrelated donors.","volume":"42","author":"Shaffer","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi260654r9","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1001\/jamaoncol.2025.4551","article-title":"Unrelated donor age and recipient outcomes after posttransplant cyclophosphamide vs conventional prophylaxis.","volume":"12","author":"Mehta","year":"2025","journal-title":"JAMA Oncol"},{"issue":"3","key":"zoi260654r10","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/s41375-025-02857-3","article-title":"Modeling donor age and type trade-offs for personalized selection in allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide prophylaxis.","volume":"40","author":"Mehta","year":"2026","journal-title":"Leukemia"},{"key":"zoi260654r11","doi-asserted-by":"publisher","DOI":"10.1200\/OP-25-00675","article-title":"Re-evaluating donor selection priorities for hematopoietic cell transplantation with post-transplant cyclophosphamide.","volume":"OP2500675","author":"Mehta","year":"2026","journal-title":"JCO Oncol Pract"},{"issue":"11","key":"zoi260654r12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.08.011","article-title":"The impact of isolated HLA-DQB1 mismatch and donor age in unrelated donor hematopoietic cell transplantation with post-transplant cyclophosphamide.","volume":"31","author":"Mehta","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"zoi260654r13","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.jtct.2025.05.019","article-title":"Choosing between HLA-mismatched unrelated and haploidentical donors: donor age considerations.","volume":"31","author":"Mehta","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"zoi260654r14","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v084.i02","article-title":"Weighted Cox regression using the R package coxphw.","author":"Dunkler","year":"2018","journal-title":"J Stat Softw"},{"issue":"2","key":"zoi260654r15","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1080\/00031305.2016.1154108","article-title":"The ASA statement on P values: context, process, and purpose.","volume":"70","author":"Wasserstein","year":"2016","journal-title":"Am Stat"},{"issue":"4","key":"zoi260654r16","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1053\/j.seminhematol.2016.07.003","article-title":"Mismatched unrelated donor transplantation.","volume":"53","author":"Petersdorf","year":"2016","journal-title":"Semin Hematol"},{"issue":"3","key":"zoi260654r17","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/s41375-021-01448-2","article-title":"Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study.","volume":"36","author":"Moorman","year":"2022","journal-title":"Leukemia"},{"issue":"13","key":"zoi260654r18","doi-asserted-by":"publisher","first-page":"3370","DOI":"10.1182\/bloodadvances.2024015238","article-title":"Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutations.","volume":"9","author":"Shah","year":"2025","journal-title":"Blood Adv"},{"issue":"1","key":"zoi260654r19","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41408-026-01479-x","article-title":"Impact of allogeneic stem cell transplantation in patients with higher risk myelodysplastic syndromes.","volume":"16","author":"Bazinet","year":"2026","journal-title":"Blood Cancer J"},{"issue":"12","key":"zoi260654r20","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"8","key":"zoi260654r21","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1001\/jamaoncol.2024.0985","article-title":"Measurable residual FLT3 internal tandem duplication before allogeneic transplant for acute myeloid leukemia.","volume":"10","author":"Dillon","year":"2024","journal-title":"JAMA Oncol"},{"key":"zoi260654r22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.10.012","article-title":"Peripheral blood or bone marrow grafts for mismatched unrelated donors with post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis.","author":"Arcuri","journal-title":"Transplant Cell Ther"},{"issue":"20","key":"zoi260654r23","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"key":"zoi260654r24","unstructured":"ClinicalTrials.gov. A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (ACCELERATE). NCT06859424. Accessed May 27, 2026. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06859424"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2851787\/mehta_2026_oi_260654_1783967641.194.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T15:30:33Z","timestamp":1784561433000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2851787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.23265","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]}}}